Analysis
Simulating Trials Before Patients Enroll
QuantHealth raised a $45 million Series B led by Qumra Capital, with Pitango HealthTech, Sanofi Ventures and several other healthcare-focused funds participating, according to MedCity News. The company builds AI models that simulate clinical trials before a single patient enrolls, aiming to catch failed trial designs and dosing problems on a computer rather than in a multi-year, multi-hundred-million-dollar study.
“The funds will go toward expanding beyond the company's current oncology, cardiometabolic and inflammatory-disease focus into more than 40 indications.”
The traction numbers are specific and checkable: QuantHealth has simulated more than 600 clinical trials across 30 indications, claiming up to 90% predictive accuracy, and currently partners with 12 of the top 20 pharmaceutical companies globally, per HIT Consultant. That partner list matters more than most funding-round customer counts because pharma companies rarely attach their name to an unproven vendor given how much regulatory and financial risk sits inside a Phase 3 trial design.
The competitive landscape includes larger clinical-AI players like Unlearn.AI and Certara, both pursuing overlapping trial-simulation and digital-twin approaches, plus in-house data science teams at major pharma companies who are QuantHealth's real alternative in most deals. The funds will go toward expanding beyond the company's current oncology, cardiometabolic and inflammatory-disease focus into more than 40 indications.
The caveat worth noting: predictive accuracy claimed on retrospective simulation of trials that already happened is a different, easier bar than prospectively predicting a trial's outcome before it runs -- the real test of QuantHealth's model is how many of its live recommendations actually change a trial design that then succeeds. What to watch: the company's first publicly disclosed case where a QuantHealth-recommended design change altered a real trial's outcome.